JW Therapeutics Announces Two Appointments to Strengthen R&D Capability and Pipeline Building

SHANGHAI, Jan. 9, 2022 /PRNewswire/ — JW Therapeutics (HKEx: 2126), an independent, innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products, recently announced the appointments of Dr. Shaun Paul Cordoba as Chief Scientific Officer (CSO) and Raymond J. Hage, Jr. as Senior Vice President (SVP) of Corporate Development. In the newly created CSO role, Dr. Cordoba will oversee the early-stage research and development, and provide scientific leadership and strategic guidance to develop a robust cell immunotherapy pipeline. As SVP of Corporate Development, Mr. Hage will lead corporate strategy development and business partnerships to enhance and build the near and long-term pipeline.

Dr. Cordoba is a highly regarded scientist in driving new innovations in cell immunotherapy technology. He is ranked 3rd in the world for patent holdings in relation to Chimeric Antigen Receptor (CAR) technology with well over 270 patent filings in relation to enhancing CAR activity, shielding CAR-T cells from immunosuppression, and improving CAR safety. Prior to joining JW Therapeutics, Dr. Cordoba was the Executive Director of Synthetic Biology and Cell Signalling at Autolus Therapeutics, where he led a group of scientists focused on the development of Chimeric Antigen Receptors (CARs) for both haematological and solid tumors. He holds a Ph.D. in Immunology from the University of Sydney and held post-doctoral positions at the University of Oxford, Imperial College London, and University College London.

Mr. Hage has a strong business acumen and rich experience in biotech and pharmaceutical industry. He is a founder of Hapten Sciences, and an advisor to companies and venture funds in the biotech and vaccine industry. Before that, he served as Senior Vice President of Commercial Operations and Chief Operating Officer of Novavax, Inc., a publicly traded vaccine company. During his career, Mr. Hage has led several functions including product development, corporate strategy, commercial operations and corporate development, and held a variety of positions with Cephalon (Teva) and Eli Lilly & Co. Mr. Hage holds an MBA degree from Fisher College of Business from The Ohio State University.

James Li, Co-founder, Chairman and CEO of JW Therapeutics, commented: “The additions of of Dr. Cordoba and Mr. Hage to our senior leadership team bring a wealth of knowledge, experience, expertise that will be vital to JW Therapeutics during the next stage of growth. We will continue to optimize the technology platform to expand our product pipelines, to deliver breakthrough cell immunotherapy products to patients.”

Reference:
Nature Biotechnology, vol38, p1387-1394, 2020.

About JW Therapeutics

JW Therapeutics (HKEx: 2126) is an independent, innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products. Co-founded by Juno Therapeutics (a Bristol Myers Squibb company) and WuXi AppTec in 2016, JW Therapeutics is committed to becoming an innovation leader in cell immunotherapy. The company has built a top world-class platform for technology and product development in cell immunotherapy, as well as a promising product pipeline covering both hematologic malignancies and solid tumors, to bring the hope of a cure for Chinese and global patients, and to lead the healthy and standardized development of China’s cell immunotherapy industry. For more information, please visit www.jwtherapeutics.com.

Forward-Looking Statements

The forward-looking statements are based on the management’s expectations and beliefs and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described. Significant risks and uncertainties, include those discussed below and more fully described in Hong Kong Exchanges and Clearing Limited (HKEx) reports filed by the Company. Unless otherwise noted, the Company is providing this information as of the date it publicized, and expressly disclaims any duty to update information contained in the issues and relevant information, or provide any explanation. For detailed information, please visit the company website: www.jwtherapeutics.com/en/forward-looking-statements/.

Cision View original content: https://www.prnewswire.com/news-releases/jw-therapeutics-announces-two-appointments-to-strengthen-rd-capability-and-pipeline-building-301456682.html

SOURCE JW Therapeutics

Note: This article have been indexed to our site. We do not claim legitimacy, ownership or copyright of any of the content above. To see the article at original source Click Here

Related Posts
Ukraine Just Blew Up Russia’s Main Missile Base In Occupied Crimea thumbnail

Ukraine Just Blew Up Russia’s Main Missile Base In Occupied Crimea

An S-400 battery explodes in Crimea.Ukrainian intelligence collection After capturing Ukraine’s Crimean Peninsula in February 2014, the Russian armed forces established a major missile base on Cape Tarkhankut in western Crimea. There, the Russians deployed an S-400 surface-to-air missile battery, a battery armed with Bastion anti-ship cruise missiles and a suite of radars including a
Read More
Material Takeoff: What Is It & Why It Is Essential in Construction thumbnail

Material Takeoff: What Is It & Why It Is Essential in Construction

Arguably one of the most essential documents to ensure a construction project’s success, a material takeoff (MTO) is a comprehensive list of all materials and their quantities required to complete a project derived from the construction drawings and plans. Also referred to as a construction takeoff, quantity takeoff, or simply a takeoff, is a crucial
Read More
Ontario dealer CanLift steps into earthmoving with XCMG agreement thumbnail

Ontario dealer CanLift steps into earthmoving with XCMG agreement

When fully up and running, CanLift will be able to offer the full line of XCMG earthmoving machines, including excavators, compactors, skid-steers, and more."We're concentrating on mini-excavators to start. We're going to be strategic about it - we're not bringing in everything they have immediately," Dragicevic said. "We're starting with the excavators and rollers, and…
Read More
Las acciones de Moderna se apalancan en un anuncio clave para 2022 thumbnail

Las acciones de Moderna se apalancan en un anuncio clave para 2022

Moderna dice que tiene pedidos de vacunas por US$ 18.500 millones para 2022, lo que le asegura beneficios extraordinarios.Además, la compañía estadounidense de biotecnología señaló que las ventas de vacunas durante el año que pasó representaron más de 17 mil millones de dólares, cifra que ha sido más alta que el promedio que estimaron los…
Read More
Gilbert Ash wins £22m Brighton College arts centre thumbnail

Gilbert Ash wins £22m Brighton College arts centre

Grant Prior 4 days ago Gilbert-Ash, has been appointed main contractor on a £22m project to develop a building for the performing arts at Brighton College. The contractor will start on site later this month with the scope of works including the demolition of existing buildings and the construction of a 400-seat multifunctional theatre, dance…
Read More
Airbnb CEO Dabbles With Adding Crypto Payments in 2022 thumbnail

Airbnb CEO Dabbles With Adding Crypto Payments in 2022

American home rental firm Airbnb Inc. might soon join the growing list of companies that accept cryptocurrencies as payment options for services. Airbnb to Accept Crypto Payments? The possibility of Airbnb supporting crypto payments comes after the company’s co-founder, and CEO Brian Chesky asked users on Twitter to recommend anything they would like the home…
Read More
Index Of News
Total
0
Share